NeuMedicine International

NeuMedicine International is a clinical-stage biopharmaceutical company dedicated to developing innovative small molecule therapeutics for central nervous system (CNS) disorders. The company's pipeline focuses on multi-target ligands and bifunctional compounds designed to address the complex pathology of neurodegenerative diseases and psychiatric conditions. Their lead programs target indications such as Alzheimer's disease, Parkinson's disease, and chronic pain by modulating neuroinflammation and neuroprotection pathways. NeuMedicine leverages research originating from Virginia Commonwealth University to create disease-modifying treatments. The company has been supported by multiple grants from the National Institutes of Health (NIH) to advance its drug candidates through early clinical development.